University of Marburg

Blue Faery Awards Liver Cancer Research Grant

Retrieved on: 
Monday, April 8, 2024
HCC, Research, Fairy, Internal medicine, Liver cancer, AstraZeneca, Professor, Caregiver, Patient, Education, Hepatocellular carcinoma, Heidelberg University, Culture, Teaching hospital, University of Marburg, Neoplasm, Cancer, LOS, Gastrointestinal disease, Multimedia, BFA

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Blue Faery created the award to recognize medical professionals who do innovative HCC research.

Key Points: 
  • Dr. Peter Galle, Professor and Chairman at University Medical Center Mainz, wins a $25K grant
    LOS ANGELES, April 8, 2024 /PRNewswire/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the annual Blue Faery Award (BFA) for Excellence in Liver Cancer Research.
  • Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy.
  • Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer .
  • Blue Faery has three public education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

Kyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North America

Retrieved on: 
Wednesday, June 21, 2023
Vaccine, Monoclonal antibody, La Jolla Institute for Immunology, Scripps Research, Society, University, Senior, Bachelor of Science in Human Biology, CSO, American Association for Cancer Research, Kyowa Kirin, Journal, CAR, American Society of Clinical Oncology, Patient, University of Greifswald, Potyvirus, Drug discovery, Human biology, Immunology, Spacecraft, Caregiver, TSE, University of Marburg, Pharmaceutical industry, Nursing, Science, Immunotherapy, Cancer, Chemistry, Research, Biology

PRINCETON, N.J., June 21, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company, today announced that Gunnar Kaufmann, Ph.D., has been named Chief Research Officer (CRO). Dr. Kaufmann joins Kyowa Kirin North America (KKNA) from Oncternal Therapeutics, Inc., where he served as Chief Scientific Officer. In his new role, Dr. Kaufmann will oversee KKNA's team of researchers based in La Jolla, CA, as well as the Open Innovation Department, which seeks external partnerships to accelerate drug discovery and the application of new biotechnologies. He also serves as an Adjunct Assistant Professor at The Scripps Research Institute in the Departments of Chemistry and Immunology and Microbial Science.

Key Points: 
  • Dr. Kaufmann Joins from Oncternal Therapeutics, Inc.
    PRINCETON, N.J., June 21, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company, today announced that Gunnar Kaufmann, Ph.D., has been named Chief Research Officer (CRO).
  • Dr. Kaufmann joins Kyowa Kirin North America (KKNA) from Oncternal Therapeutics, Inc., where he served as Chief Scientific Officer.
  • He also serves as an Adjunct Assistant Professor at The Scripps Research Institute in the Departments of Chemistry and Immunology and Microbial Science.
  • "Dr. Kaufmann's proven track record of leading drug discovery, research, and preclinical development will help Kyowa Kirin grow our future pipeline with new drug targets and therapeutic candidates that have the potential to address patients' unmet needs," said Yoshifumi Torii, Ph.D., Global Research Head of Kyowa Kirin.

Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives

Retrieved on: 
Wednesday, July 6, 2022
Department, Miami University, Sofinnova, University of Marburg, DMPK, Research, Precision medicine, Head, MJFF, Therapy, Pharmacokinetics, Enzyme, Investment, Metabolomics, BMS, Biomarker, GLOBE, Cancer, Lists of diseases, The Michael J. Fox Foundation, Genentech, Amgen, Neuroscience, SAN, PCT, Sheerin, University of California, San Francisco, Bristol Myers Squibb, Drug discovery, University, Drug metabolism, Cardiovascular disease, CA, Degenerative disease, Vanderbilt University, ICF, Doctor of Philosophy, Pharmaceutical industry, Biochemistry, Chemistry, Merck

Frank and Sheerin each bring over 20 years of experience in drug discovery and development for both biotech and large pharma.

Key Points: 
  • Frank and Sheerin each bring over 20 years of experience in drug discovery and development for both biotech and large pharma.
  • Before Nitrase Therapeutics, Dr. Kayser was the chief scientific officer and senior vice president of drug discovery at BioArdis, where he spearheaded all aspects of small molecule discovery.
  • Prior to joining Nitrase Therapeutics, she served as a senior director of the ICF disease team and translational medicine at Bristol Myers Squibb (BMS).
  • Nitrase Therapeutics is located in Brisbane, CA, and its investors include Sofinnova Partners, AbbVie Ventures, Dementia Discovery Fund, Bristol Myers Squibb, Mission Bay Capital and Alexandria Venture Investments.

Kaia Health Improves Access to Care for 15+ Million Individuals Living with Breathing-Related Health Conditions in North America with Launch of its COPD Digital Therapy

Retrieved on: 
Wednesday, June 8, 2022
Health, Medical Devices, Infectious Diseases, Technology, Practice Management, Software, Clinical Trials, Exercise, Randomized controlled trial, Korea Disease Control and Prevention Agency, MSK, COPD, Canadian International Council, Chronic obstructive pulmonary disease, Respiratory disease, Health status of Asian Americans, DTA, BMI, Therapy, Solution, University, Physician, Center, Patient, Technology, University of Marburg, COVID-19, Rehabilitation, Quality of life, PR, RCT, Industry, International Journal of Chronic Obstructive Pulmonary Disease, Smartphone, Kaia, Death, Lists of diseases, Health, Pharmaceutical industry, Health insurance, Hospital, Thorax

COPD refers to a group of conditions that cause airflow blockage and breathing-related problems, including emphysema and chronic bronchitis.

Key Points: 
  • COPD refers to a group of conditions that cause airflow blockage and breathing-related problems, including emphysema and chronic bronchitis.
  • While there is no cure for the condition, COPD can be treated using digital therapeutic pulmonary rehabilitation (PR) solutions like those developed by Kaia Health.
  • Built on the Kaia Health digital therapy platform, the Kaia Health COPD app digitizes and delivers affordable, accessible, physical PRconsidered the gold standard in COPDdirectly to patients homes on their smartphones.
  • Kaia Health is the worlds largest digital therapeutics company that creates accessible, evidence-based treatments for a range of conditions, including MSK pain and COPD.

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

COPD Study Shows: Using the Kaia Health App, Positive Effects of Inpatient Rehabilitation Are Maintained Longer

Retrieved on: 
Tuesday, April 26, 2022
Science, Software, Biotechnology, Practice Management, Research, Physical Therapy, Health, Technology, American Thoracic Society, Congestion, COPD, Health status of Asian Americans, Cough, Kaia, Research, Health, Life, Rehabilitation, DTA, University of Marburg, Patient, Smartphone, Technology, CAT, Therapy, Concept, Chronic Respiratory Disease, Tightness, MSK, Physician, Disease, University, BMI, Exercise, Time, Hospital, Medical imaging, Medical device, Health insurance

As a result, researchers found that with Kaia Health, improvements from inpatient rehabilitation were maintained over the entire study period of six months - compared to the control group.

Key Points: 
  • As a result, researchers found that with Kaia Health, improvements from inpatient rehabilitation were maintained over the entire study period of six months - compared to the control group.
  • The Kaia Health COPD app has been proven to be an innovative way of positively influencing the health status of COPD patients over a longer period of time.
  • "With Kaia Health, the success of the inpatient rehabilitation over six months was maintained to the greatest extent during the study.
  • When using Kaia Health, patients with COPD are no longer on their own after inpatient rehabilitation.

Graybug Vision Appoints Dirk Sauer to Board of Directors

Retrieved on: 
Wednesday, April 13, 2022
Glycogen storage disease, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Timolol, Eye, Research, GLOBE, Patient, Technology, Forward-looking statement, Lists of diseases, University, Annual report, Human, Stroke, Nomination, Private Securities Litigation Reform Act, AMD, Doctor of Philosophy, Board for International Food and Agricultural Development (BIFAD), Neuroscience, Retina, Science, Ranibizumab, CGMP, Retinitis pigmentosa, Verteporfin, ALS, Board, Ophthalmology, Leadership, Therapy, Time, ODD, International development, Cornea, Johns Hopkins School of Medicine, Optic nerve, University of Marburg, Form 10-K, AAV, Injury, Diabetic retinopathy, Pharmaceutical industry, Management, Novartis, Pharmacology, Pharmacy

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022.

Key Points: 
  • BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022.
  • Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Board after eight years of service.
  • Dr. Cagle will continue to advise the Graybug Executive Team and the Board as a member of the Science and Innovation Committee.
  • We are pleased to welcome Dirk Sauer to the Board as Jerrys successor.

ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem

Retrieved on: 
Monday, September 20, 2021
Adoption, University of Marburg, Miss California USA, Artificial intelligence, Compliance, Workflow, Sale, Suction, Surgeon, Patient, Professor, Physician, MD, Digital technology, Diabetes, ZO, Environment, CEO, Medicine, Face, Ophthalmology, Technology, Automation, IOP, Data analysis, Doctor of Philosophy, ZEISS, Gyration tensor, Medical device, 3D printing, Telescopic sight

ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.

Key Points: 
  • ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.
  • This revolution in phaco technology includes the ZEISS patented QUATTRO Pumpwhich delivers chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The QUATERA 700 increases a surgeon's workflow efficiency from the clinic to the operating room, enabling one digitally integrated surgical workflow.
  • *ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in some markets.

ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem

Retrieved on: 
Monday, September 20, 2021
Adoption, University of Marburg, Miss California USA, Artificial intelligence, Compliance, Workflow, Sale, Suction, Surgeon, Patient, Professor, Physician, Data management, MD, Digital technology, Diabetes, ZO, Environment, CEO, Medicine, Face, Ophthalmology, Technology, Automation, IOP, Data analysis, Doctor of Philosophy, ZEISS, Gyration tensor, Medical device, 3D printing, Telescopic sight

JENA, Germany and DUBLIN, Calif., Sept. 20, 2021 /PRNewswire/ -- At ZEISS Innovation Week, September 21- 23, 2021, ZEISS Medical Technology will introduce industry-first, integrated solutions that bring further value to the ZEISS Medical Ecosystem, connecting devices, data and applications that will help maximize clinical efficiency and performance.

Key Points: 
  • ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*.
  • This revolution in phaco technology includes the ZEISS patented QUATTRO Pumpwhich delivers chamber stability independent of intra-ocular pressure (IOP) and flow.
  • The ZEISS Cataract Workflow is further enhanced with two new and original surgical software applications.
  • *ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in some markets.